4/30 Late treatment study
et al., South. Clin. Ist. Euras., doi:10.14744/scie.2021.89847 (Peer Reviewed)
The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in Geriatric Patients
The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in Geriatric Patients
Retrospective 147 ICU patients in Turkey, showing no significant difference in outcomes based on HCQ treatment before ICU admission. This is not very informative, for example we do not know if HCQ treated patients were much less likely to be admitted to the ICU.
Çiyiltepe et al., 4/30/2021, retrospective, Turkey, Europe, peer-reviewed, 5 authors.
risk of death, 3.2% lower, RR 0.97, p = 0.85, treatment 69 of 95 (72.6%), control 39 of 52 (75.0%).
This study is excluded in the after exclusion results of meta analysis: treatment group only includes patients where treatment failed resulting in ICU admission.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.